Gossamer Bio
GOSS
86 hedge funds and large institutions have $632M invested in Gossamer Bio in 2019 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 30 increasing their positions, 20 reducing their positions, and 10 closing their positions.
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
50% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 20
10% more funds holding
Funds holding: 78 → 86 (+8)
8% less capital inflows, than outflows
Capital inflows: $86.8M | Capital outflows: $94.8M
1.5% less ownership
Funds ownership: 62.7% → 61.2% (-1.5%)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
91% less call options, than puts
Call options by funds: $1.54M | Put options by funds: $16.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$18.1M |
| 2 |
BlackRock
New York
|
+$15M |
| 3 |
Farallon Capital Management
San Francisco,
California
|
+$8.04M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$7.22M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$17.8M |
| 3 |
Baupost Group
Boston,
Massachusetts
|
-$15.9M |
| 4 |
Omega Fund Management
Boston,
Massachusetts
|
-$8.74M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.58M |
GOSS Hedge Fund Activity: Q4 2019 in Review
86 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q4 2019, worth a combined $632M — down 8.9% from $694M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new GOSS positions and 10 closed out — a net gain of 14 holders — while 30 added to existing stakes and 20 trimmed.
The largest buyer was State Street, adding an estimated $18.1M. The largest seller was Fidelity Investments, cutting an estimated $17.9M.
- 86 institutional investors held Gossamer Bio (GOSS) as of Q4 2019, up from 78 in Q3 2019.
- Funds reported $632M of Gossamer Bio stock for Q4 2019, down 8.9% quarter-over-quarter.
- 24 funds opened new Gossamer Bio positions in Q4 2019 and 10 closed out, a net change of +14 holders.
- The largest Gossamer Bio buyer in Q4 2019 was State Street, an estimated $18.1M added.
- The largest Gossamer Bio seller in Q4 2019 was Fidelity Investments, an estimated $17.9M sold.
Based on aggregated 13F filings for Q4 2019.